Valuation: Hemostemix Inc.

Market Cap 14.84M 10.78M 9.23M 8.64M 7.91M 1.03B 15.03M 102M 39.79M 518M 40.46M 39.58M 1.71B P/E 2024
-4.36x
P/E 2025 -3.12x
Enterprise Value 17.7M 12.85M 11.01M 10.3M 9.43M 1.23B 17.93M 122M 47.46M 618M 48.26M 47.21M 2.04B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
82.85%
Yield 2024 *
-
Yield 2025 -
1 day-6.25%
1 week+15.38%
Current month+25.00%
1 month+15.38%
3 months+50.00%
6 months-11.76%
Current year-16.67%
1 week 0.07
Extreme 0.07
0.08
1 month 0.06
Extreme 0.06
0.08
Current year 0.04
Extreme 0.04
0.11
1 year 0.04
Extreme 0.04
0.14
3 years 0.04
Extreme 0.035
0.42
5 years 0.04
Extreme 0.035
0.42
10 years 0
Extreme 0
5.9
Manager TitleAgeSince
Chief Executive Officer - 2020-02-09
Director of Finance/CFO - 2020-03-04
Chief Tech/Sci/R&D Officer - 2021-10-13
Director TitleAgeSince
Director/Board Member - 2019-11-25
Director/Board Member 67 2020-02-08
Director/Board Member - 2020-04-07
Date Insider Type Main position Quantity % Market Cap.
7/30/26 Option

Chairman

525,000 0.2654%
7/22/26 Option

Director

385,000 0.1946%
7/22/26 Option

Founder

1,730,000 0.8746%
Change 5-day change 1-year change 3-year change Capi.($)
-6.25%+15.38%-11.76%-48.28% 10.78M
-3.00%+2.27%+77.60%+109.33% 72.12B
+1.90%+23.53%+56.60%+97.76% 65.85B
+5.12%+25.22%+5.24%-0.82% 29.28B
+0.55%+1.64%-5.15%+471.68% 27.47B
+2.74%+12.98%+62.84%+28.14% 26.7B
+0.47%+6.12%+36.66%-13.79% 20.06B
+1.82%-6.67%+247.46%+393.10% 18.22B
+0.94%+3.36%+18.55%+532.94% 16.4B
+0.73%+5.54%+39.71%+153.07% 13.4B
Average +0.50%+9.07%+52.77%+172.31% 28.95B
Weighted average by Cap. +0.74%+9.48%+59.04%+157.80%

Financials

2024 2025
Net sales - -
Net income -2.62M -1.9M -1.63M -1.52M -1.39M -182M -2.65M -17.99M -7.02M -91.33M -7.14M -6.98M -302M -4.71M -3.42M -2.93M -2.74M -2.51M -328M -4.78M -32.42M -12.64M -165M -12.86M -12.58M -544M
Net Debt 4.23M 3.07M 2.63M 2.46M 2.25M 294M 4.29M 29.1M 11.35M 148M 11.54M 11.29M 489M 2.86M 2.08M 1.78M 1.67M 1.52M 199M 2.9M 19.68M 7.67M 99.87M 7.8M 7.63M 330M
Logo Hemostemix Inc.
Hemostemix Inc. is an autologous stem cell therapy platform company. The Company has developed, patented, and is scaling and selling autologous (patient’s own) blood-based stem cell therapies that include angiogenic cell precursors (ACP-01), later neural cell precursors (NCP-01), and cardiomyocyte cell precursors (CCP-01). It holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including ACP-01, CCP-01 and NCP-01. ACP-01 is a clinically relevant and statistically significant treatment for peripheral arterial disease, chronic limb-threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. It has completed a Phase II clinical trial for chronic limb-threatening ischemia. It has two wholly owned subsidiaries, Kwalata Trading Limited and PreCerv Inc. PreCerv Inc. holds a global field of use license to ACP-01 & NCP-01 for the treatment of conditions of the central and peripheral nervous system.
Employees
-
Date Price Change Volume
26-08-21 $0.0750 -6.25% 5,629
26-08-19 $0.0800 +6.67% 11,001
26-08-18 $0.0750 0.00% 1,000
26-08-17 $0.0750 +15.38% 11,920
26-08-14 $0.0650 -7.14% 3,824